Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
16.62
+0.54 (3.36%)
Nov 21, 2024, 11:32 AM EST - Market open
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
202.42M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
InfuSystem Holdings | 132.78M |
Personalis | 87.49M |
Enanta Pharmaceuticals | 71.96M |
ADC Therapeutics | 70.72M |
Editas Medicine | 61.76M |
Profound Medical | 8.98M |
Orchestra BioMed Holdings | 2.65M |
CRBP News
- 10 days ago - Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies - Seeking Alpha
- 23 days ago - Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire
- 5 weeks ago - Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit - GlobeNewsWire
- 2 months ago - Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now - Benzinga
- 3 months ago - Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say - Market Watch
- 3 months ago - Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire